Ocata receives SBIR grant to develop HMC therapy for lupus nephritis
24 August 2015 | By Victoria White
Ocata has been awarded a SBIR Phase 1 grant to fund further preclinical development of Ocata’s proprietary Hemangio-derived Mesenchymal Cell (HMC) product...